Should Patients with Drug-Resistant HIV-1 Continue to Receive Antiretroviral Therapy?
Authors:
- Lisa M. FrenkelLFLisa M. Frenkel
- James I. MullinsJMJames I. Mullins
- 15 February 2001
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 344 (7) , 520-522
Abstract
The ultimate goal of antiretroviral therapy for patients with human immunodeficiency virus type 1 (HIV-1) infection is to cure the infection. Failing that, the objective is to stop the progression of the disease and allow the immune system some degree of recovery. Failing that, therapy is used to slow the disease process and buy patients time, during which new and better therapies may be discovered.The strong correlation between the amount of HIV-1 circulating in the blood and the rate at which AIDS develops1 has allowed measurements of viral RNA in the blood plasma to be used as a ready . . .Keywords
This publication has 13 references indexed in Scilit:
- Virologic and Immunologic Consequences of Discontinuing Combination Antiretroviral-Drug Therapy in HIV-Infected Patients with Detectable ViremiaNew England Journal of Medicine, 2001
- Association of Initial CD4 Cell Count and Viral Load With Response to Highly Active Antiretroviral TherapyJAMA, 2000
- Altered Viral Fitness of HIV-1 Following Failure of Protease Inhibitor-Based TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- HIV Genotype and Phenotype—Arresting Resistance?JAMA, 2000
- High Levels of Drug‐Resistant Human Immunodeficiency Virus Variants in Patients Exhibiting Increasing CD4+T Cell Counts Despite Virologic Failure of Protease Inhibitor–Containing Antiretroviral Combination TherapyThe Journal of Infectious Diseases, 2000
- Sustained CD4+T Cell Response after Virologic Failure of Protease Inhibitor–Based Regimens in Patients with Human Immunodeficiency Virus InfectionThe Journal of Infectious Diseases, 2000
- Antiretroviral Therapy in AdultsJAMA, 2000
- Drug Susceptibility in HIV Infection After Viral Rebound in Patients Receiving Indinavir-Containing RegimensJAMA, 2000
- The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individualsAIDS, 1999
- Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in PlasmaScience, 1996